

Bulletin from the Annual General Meeting of Devyser Diagnostics AB (publ) held on 6 May 2026

The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Wednesday, 6 May 2026 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed at the Meeting include the following.

Income statement and balance sheet as well as consolidated income statement and balance sheet

It was resolved to adopt the income statement and balance sheet, as well as the consolidated income statement and balance sheet, included in the Company's annual report.

It was resolved, pursuant to the proposal from the Board of Directors, that all profits available to the Annual General Meeting, amounting to SEK 221,149,791, should be carried forward.

The Board of Directors and Auditor

It was resolved to discharge the members of the Board of Directors and the Chief Executive Officer from liability in relation to their management of the Company's operations during the period covered by the audit report.

It was resolved that the number of members of the Board of Directors appointed by the Annual General Meeting shall be five, following Isabelle Ducellier's decision to decline re-election. It was resolved that the number of auditors should continue to be one.

For the period until the end of the next Annual General Meeting, Mia Arnhult, Fredrik Dahl, Pia Gideon, Thomas Eklund and Olof Ericsson were re-elected as members of the Board of Directors. Isabelle Ducellier had declined re-election.

For the period until the end of the next Annual General Meeting, Mia Arnhult was re-elected as Chairman of the Board of Directors. It was resolved to, for the period until the end of the next Annual General Meeting, re-elect the auditing firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. It was noted that the authorised public accountant Magnus Lagerberg would be auditor-in-charge.

Fees to the Board of Directors and the Auditor

It was resolved to approve the fees to the Board of Directors as proposed by the Nomination Committee, entailing a fee of SEK 435,000 to the Chairman and a fee of SEK 210,000 to each of the other members of the Board of Directors, amounting to a total fee of SEK 1,275,000. The Annual General Meeting further resolved that a member of the Board of Directors who is also the Chairman of the Audit Committee shall be entitled to an additional fee of SEK 65,000, and a member of the Board of Directors who is also a member of the Audit Committee shall be entitled to an additional fee of SEK 25,000.

The Annual General Meeting approved the Nomination Committee's proposal that the auditor's fee shall be paid according to an approved invoice.

Authorisation for the Board of Directors to resolve upon share issues

It was resolved, in accordance with the Board of Directors' proposal, to authorise the Board to resolve upon issues of shares, with deviation from the shareholders' preferential rights, of in aggregate at most the number of shares corresponding to at most ten (10) per cent of the total number of outstanding shares in the Company at the time of the Annual General Meeting 2026, or convertibles exchangeable for that number of shares, to the extent that an issue can be made without amendment to the articles of association.

Resolution on the introduction of a long-term performance-based incentive programme 2026 (LTIP 2026) and issue and transfer of warrants

It was resolved, in accordance with the Board of Directors' proposal, to introduce a long-term performance-based incentive programme 2026 ("LTIP 2026") directed at certain current and future employees and other key persons of the Company, comprising in total approximately 115 participants and at most 75,000 shares in the Company.

It was further resolved, in accordance with the Board of Directors' proposal, to carry out a directed issue of at most 98,565 warrants to the Company's subsidiary Devyser AB, entailing an increase in the share capital upon full exercise of at most SEK 5,656.65 and a dilution of approximately 0.59 per cent of the total number of shares and votes in the Company, and to approve the transfer of the warrants in accordance with the Board of Directors' proposal. The purpose of the issue and the transfer is to enable the delivery of performance shares in LTIP 2026 and to hedge thereto relating costs, primarily social security contributions.

For more information, please contact:

Jan Wahlström, CEO

Email: ir@devyser.com

Telephone: +46 8 562 158 50

Sabina Berlin, CFO

Email: ir@devyser.com

Telephone: +46 8 562 158 50



PRESS RELEASE
06 May 2026 13:30:00 CEST

About Devyser

Devyser is redefining how laboratories approach genetic testing. As your true one-stop shop, we offer streamlined solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). Redeye Nordic Growth AB is the company's Certified Adviser.

Discover how we're shaping the future of lab diagnostics at www.devyser.com.